Fluence LED Solutions Pave the Way for Optimizing Success in Urban Medicinal Cannabis Grow
10.5.2023 14:30:00 CEST | Business Wire | Press Release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its success in supporting Trichome, an Israeli facility growing world-class medicinal cannabis, to prove the concept of two-tiered vertical farming in an urban center.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005315/en/
Fluence LEDs inside Trichome's urban facility have supported 17 full crop growing cycles, all with greater than expected results. (Photo: Business Wire)
To successfully launch an urban vertical growing facility in Qiryat Gat, Israel, Trichome needed to collaborate with the right solution partners to maximize space while optimizing quality and automation at every step of the process. To appropriately design for the compact, intricate indoor environment and complexities associated with tiered growing, Trichome turned to Fluence for its market-leading LED lighting solutions, local service capabilities through Fluence's Israeli distribution partner, REMY, and in-house horticultural experts to assist with planning, installing and managing the deployment of integrated lighting technology.
“By partnering with Fluence, we were not reinventing the wheel but choosing the best wheels in the market,” said Tony Levi, co-founder and CEO of Trichome. “Standardization, longevity and optimization are critical factors in producing high-quality cannabis flowers. The team of experts at Fluence helped us accomplish all of those goals in an urban farm within city limits.”
Trichome installed Fluence lighting throughout its fully standardized medicinal cannabis facility. To overcome the obstacles presented by a reduction in space between crops and the artificial lights in vertical farms, Fluence worked closely with REMY, Levi and the Trichome team to understand the facility’s constraints. Ultimately, Fluence designed a bespoke system comprising its SPYDR 2i, SPYDR 2x and RAZR Modular series for Trichome. Trichome has completed 17 full crop growing cycles, all with greater than expected results using Fluence lighting—including above average yields, higher than expected terpene levels and high cannabinoid content.
“We are thrilled by the response of our plants to the Fluence LED lighting,” said Steve Abboud, head grower at Trichome. “Our cannabis crops are taking in the light from Fluence fixtures and expressing its quality through their flowering. We have been able to standardize light intensity, harness control over our cultivation methods and achieve crop uniformity because of Fluence LEDs.”
“Working with Trichome on lighting solutions has been an exciting and ambitious process where both parties learned a tremendous amount,” said Jörg Meyer-Brenken, lead account manager, cannabis EMEA at Fluence. “The product Trichome supplies is outstanding, but the feedback from the market and patients makes me even prouder. Trichome has been able to set a new bar for urban farming.”
Fluence LED lighting solutions are available for purchase by licensed cultivators in territories in which the cultivation of cannabis is legal.
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About REMY
Established in 2008, REMY 108 LTD specializes in the planning, installation, integration and quality assurance of large-scale agronomic lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, today, it also provides agronomic lighting training at its headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow.
About Trichome
Trichome is an Israeli agritech company that combines two complementary worlds—quality cannabis agriculture and advanced cannabis technologies. The company philosophy is based on three main pillars: Indoor Growth by Advanced Technology, an international team of cannabis experts and the finest, high-end varieties. Trichome owns the largest Indoor facility for medical cannabis cultivation in the Middle East. With nine flowering rooms, the multilayer facility is spread over 7,000 square meters and has an annual production capacity of six tons of high-quality, consistent standardized inflorescence. Trichome works through several channels including its own brand and white label. For more information, visit www.trichome-il.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005315/en/
Contact information
For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 (0) 160 93335045
For North America,
Callie Neatherlin
Red Fan Communications
callie@redfancommunications.com
512-439-9720
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom